Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways
Frontiers in Pharmacology · 09.06.2025 · 16
DOI: 10.3389/fphar.2025.1586231 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.06.2025. Verfasst von Naif ALSuhaymi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medical Services, Faculty of Health Sciences, AlQunfudah, Umm Al-Qura University, Makkah, Saudi Arabia. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Liver fibrosis is considered an epidemic health problem since it can lead to several insults that can be fatal. Remogliflozin (Remo), an inhibitor of the sodium–glucose cotransporter 2 (SGLT2) protein, is one of the most recently developed antidiabetic drugs for treating type 2 diabetes mellitus (T2DM). The antidiabetic and antioxidant impacts of Remo have been demonstrated in numerous animal models; however, its antifibrotic activity remains unclear. Therefore, we planned this study to clarify the preventive activity of Remo against thioacetamide (TAA)-induced liver fibrosis in male rats, along with its anticipated pathways. Four groups of rats (n = 6) were used in our investigation: the control group; the TAA group, which received 100 mg/kg b.wt IP twice a week for 6 weeks; and the TAA + Remo groups, which were given two doses of Remo at 25 and 50 mg/kg b.wt orally, respectively, for 4 weeks in addition to TAA injections. The TAA group showed a marked increase in liver enzymes, lipid peroxidation, and proinflammatory cytokines, along with a marked decrease in albumin and cellular antioxidant status. Additionally, the TAA group showed a marked increase in nuclear factor-κB (NF-κB) and a marked decrease in AMP-activated protein kinase (AMPK), sirtuin 1 (SIRT1), and nuclear factor erythroid 2–related factor 2 (Nrf2) levels and expressions. The harmful effects of TAA were significantly mitigated by Remo therapy, which improved the aforementioned parameters. Histopathological findings corroborated the biochemical results. The results of our study suggest that Remo has anti-inflammatory and antioxidant properties that protect against TAA-induced liver fibrosis by inhibiting the NF-κB pathway and activating the AMPK/SIRT1/Nrf2 pathway.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medical Services, Faculty of Health Sciences, AlQunfudah, Umm Al-Qura University, Makkah, Saudi Arabia.
- Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Cairo, Egypt.
- Department of Pharmacology, Medical Research and Clinical Studies Institute, National Research Centre, Cairo, Egypt.
- Department for Life Quality Studies, Rimini Campus, University of Bologna, Rimini, Italy.
- Department of Molecular Food Chemistry and Food Development, Institute of Food and One Health, Gottfried Wilhelm Leibniz University Hannover, Hannover, Germany.
- Department of Pathology, College of Veterinary Medicine, Cairo University, Cairo, Egypt.
Zitieren
APA
ALSuhaymi, N., Alsugoor, M. H., Shokry, A. A., Fayed, H. M., Mohamed, B. M. S. A., Afifi, S. M., Esatbeyoglu, T., Korany, R. M. S., & Elbaset, M. A. (2025). Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1586231
Vancouver
ALSuhaymi N, Alsugoor MH, Shokry AA, Fayed HM, Mohamed BMSA, Afifi SM, et al. Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1586231
BibTeX
@article{ALSuhaymi2025,
author = {ALSuhaymi, Naif and Alsugoor, Mahdi H and Shokry, Aya A and Fayed, Hany M and Mohamed, Bassim M S A and Afifi, Sherif M and Esatbeyoglu, Tuba and Korany, Reda M S and Elbaset, Marawan A},
title = {Protective role of remogliflozin against experimental liver fibrosis by activating AMPK/SIRT1/Nrf2 and suppressing NF-κB pathways},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1586231}
}
EUVIMED